Bayesian Health became the first company to receive FDA clearance for a continuous AI-powered sepsis monitoring system. The clearance follows years of clinical validation studies and real-world deployments across multiple health systems.
Oura has filed for an IPO as it looks to build on its evolution from a sleep-focused wearable startup into a broader healthcare player.
Veradigm examines key clinical trends, comorbidity profiles, and treatment trends across adolescence, reproductive years, and peri-/post-menopause. Download it today!
London-based GHO Capital and Singapore-based CBC Group plan to merge in a deal that would create what the firms describe as the “world’s largest dedicated healthcare investment firm.” GHO has $10.5 billion assets under management, and CBC has $10.8 billion in assets under management.
Engage Bio developed a platform technology that enables non-viral delivery of DNA to cells. The acquisition is the latest in a series of Eli Lilly deals that expand the pharmaceutical company’s pipeline and capabilities in genetic medicines.
Fountain Health Partners announced its launch, with plans to back companies approaching or already at profitability, with a clear three- to five-year path to a strategic exit. The investment firm was founded by Joey Campanelli, a former executive at Shields Health Solutions, and Jack Euston, a healthcare investment banker with more than a decade of experience in M&A.
Duracyte’s implants employ cells engineered to produce therapeutic protein, bypassing the complexities of traditional biologics manufacturing. The startup’s marriage of biotechnology with electronics comes with on-board sensors that enable clinicians to monitor and control an implant’s drug production process.
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.
A new report from PayZen found that providers collect just 31% of patient bills on average, even as patient payments account for a growing share of health system revenue. PayZen executive Tobias Mezger outlined how providers can improve the patient financial experience through clearer pre-care payment conversations and more flexible financing options.
IKS Health acquired healthcare AI startup ARAI to strengthen the technology underpinning its automation tools, as well as reduce its dependence on third-party AI models.
Shyld AI has raised $13.4 million to expand its AI-powered UV disinfection platform, which autonomously sanitizes hospital rooms. The startup’s technology aims to reduce the risk of hospital-acquired infection, as well as lessen hospitals’ reliance on labor-intensive cleaning workflows.
Beth Israel Lahey Health said modernizing its fax infrastructure during a major Epic EHR consolidation helped the health system slash fax failure rates from 34% to 4% and save $4 million. By adopting Retarus’ cloud-based platform, the health system simplified referrals and prescription processing, as well as reduced manual administrative work.
Small practices play a critical role in healthcare delivery, but they cannot continue to absorb ever-increasing administrative demands without consequences.
Immunology-focused Windward Bio raised a mega-round of financing to support a lead program in development for respiratory disorders and a second program that could find use in respiratory and dermatological indications. Both drugs are long-acting antibodies that offer a dosing edge over currently available biologic medicines.
The Department of Justice’s new “West Coast” strike force targets Arizona, Nevada and Northern California — regions flagged for rising Medicaid, hospice and tech-enabled fraud risks. Legal experts say the effort signals a broader shift toward data-driven enforcement, as regulators ramp up their scrutiny of telehealth companies and billing automation software.
Pennsylvania sued Character.ai, alleging one of the startup’s AI chatbots illegally practiced medicine by posing as a licensed psychiatrist. The case marks the second state lawsuit against the startup and highlights growing regulatory scrutiny of AI chatbot platforms and their safety guardrails.
Perfuse Therapeutics brings Bayer an eye drug administered via an implant that controls the release of the therapy. This program is in mid-stage clinical development for glaucoma and diabetic retinopathy.
Roon is a new physician-only social network. The platform — founded by a neurosurgeon and two former Pinterest executives — aims to surface the “collective wisdom” of doctors that currently lives in informal exchanges and fragmented online communities.